RCEL
$4.46-0.16 (-3.46%)
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harves...
Recent News
Wall Street Analysts Believe Avita Medical (RCEL) Could Rally 29.87%: Here's is How to Trade
The consensus price target hints at a 29.9% upside potential for Avita Medical (RCEL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Avita Medical Targets “Progressive” 2026 Growth, Guides $80M-$85M Revenue After Headwind Year
Avita Medical (NASDAQ:RCEL) executives told investors they are focused on making the business more predictable and execution-driven in 2026, following what they described as a headwind-heavy 2025 that included reimbursement disruption, a sales force reconfiguration, and repeated amendments tied to r
Avita Medical (RCEL) Upgraded to Buy: Here's What You Should Know
Avita Medical (RCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AVITA Medical Inc (AVHHL) Q4 2025 Earnings Call Highlights: Navigating Growth and Challenges
AVITA Medical Inc (AVHHL) reports 11% annual revenue growth and sets optimistic guidance for 2026 amidst reimbursement and cash reserve challenges.
Avita Medical Q4 Earnings Call Highlights
Avita Medical (NASDAQ:RCEL) reported fourth-quarter revenue of $17.6 million and full-year 2025 revenue of approximately $71.6 million, representing about 11% growth over 2024 and landing in line with the company’s updated guidance, executives said on the company’s fourth-quarter and full-year 2025